CAMP4 Therapeutics (CAMP) vs Nautilus Biotechnology (NAUT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nautilus Biotechnology (NAUT) has outperformed CAMP4 Therapeutics (CAMP) over the past year, gaining 126.3% versus a gain of 16.7%. Nautilus Biotechnology is the larger company by market cap ($249.4 million vs $241.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAMP | NAUT |
|---|---|---|
| Share price | $3.84 | $1.96 |
| Market cap | $240.97M | $249.42M |
| 1-day change | -3.03% | +10.73% |
| YTD return | -37.36% | +0.51% |
| 1-year return | +16.72% | +126.33% |
| 5-year return | — | -65.67% |
| EPS (TTM) | $-2.32 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $4.31 |
| 52-week low | $2.86 | $0.82 |
| Distance from 52-week high | -50.45% | -54.52% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +175.26% | +95.41% |
| Average volume | 277.90K | 2.59M |
| Shares outstanding | 62.75M | 127.26M |
| Employees | 48 | 127 |
| Sector | Health Care | Industrials |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NAUT has outperformed CAMP by 109.6 percentage points over the past year.
- The two companies sit in different sectors: CAMP4 Therapeutics in Health Care and Nautilus Biotechnology in Industrials.
About CAMP4 Therapeutics
CAMP stock →Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Nautilus Biotechnology
NAUT stock →Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Industrials · Biotechnology: Laboratory Analytical Instruments · 127 employees
CAMP vs NAUT FAQ
Which is bigger, CAMP4 Therapeutics or Nautilus Biotechnology?
Nautilus Biotechnology (NAUT) is larger, with a market capitalization of $249.42M compared with $240.97M for CAMP4 Therapeutics (CAMP).
Which stock has performed better over the past year, CAMP or NAUT?
NAUT returned +126.33% over the past 12 months, compared with +16.72% for CAMP (price return, excluding dividends). Past performance does not predict future results.
Are CAMP4 Therapeutics and Nautilus Biotechnology in the same industry?
No. CAMP4 Therapeutics is in the Health Care sector, while Nautilus Biotechnology is in Industrials.